Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
25.90    -0.90 (-3.36%)
Bid:
25.90
Ask:
26.90
Spread: 1.00 (3.861%)
Market Cap: £111.44m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

AGM Statement

15 May 2006 10:26

Immediate Release: 15 May 2006 International Brand Licensing plc ("IBL" or the "Company") AGM Statement At today's AGM, Chairman Adam Reynolds commented:"In my statement of 19th April 2006, I was pleased to report a substantialturnaround in the Company's fortunes by producing a full year profit for thefirst time in the Company's history.I am now delighted to announce to you that the current year has startedextremely well with the first four month's sales being around 25% higher thanthe corresponding period last year, which in itself was a record year. Inaddition, the Board is continuing to drive down fixed costs and is activelylooking at ways of increasing its gross margins through both manufacturing anddistribution efficiencies.It is both reassuring and rewarding that sales of the official England Admiralreplica kit are still outperforming all our expectations and that the Companyis further benefiting from its focus on cost savings since the Board wasrestructured last year.Last week, the Company announced the sale of its Admiral trademarks for theGreece and Cyprus territories for a cash consideration of ‚£775,000, reflectingthe increasing value of the Admiral brand globally. Whilst expanding thegeographical reach of the Admiral brand remains at the core of the Company'sstrategy, our over-riding aim is to maximise shareholder value which we firmlybelieve this transaction achieved.We are currently in discussion with several potential partners regarding thesigning of new long term license agreements in regions where we are currentlynot represented. We are confident that the number of territories in which theAdmiral brand is distributed, currently 22, can be substantially increased inthe medium to long term, ensuring continued strong growth in the business goingforward.Your Board is delighted with the progress the Company has made during the yearto date and we remain confident that we will continue to improve shareholdervalue throughout the year ahead."For Further information:Adam Reynolds/Paul FoulgerInternational Brand Licensing020 7823 1733ENDINTERNATIONAL BRAND LICENSING PLC
Date   Source Headline
5th May 20207:00 amRNSDistribution Agreement for Quo-Test HbA1c Analyzer
29th Apr 20207:00 amRNSUK contract for COVID-19 sample collection kits
28th Apr 20207:00 amRNSCOVID-19 related manufacturing capacity update
27th Apr 20207:00 amRNSUpdate on COVID-19 related manufacturing contract
7th Apr 20207:00 amRNSFinal Results
24th Mar 20207:00 amRNSDetailed trading review including COVID-19 update
20th Mar 20207:00 amRNSInvestor results briefing update
4th Mar 20207:00 amRNSNotice of Results
24th Feb 20201:56 pmRNSHolding(s) in Company
29th Jan 20207:00 amRNSTrading update
6th Nov 201912:14 pmRNSTrading update and performance bonuses
10th Sep 20197:00 amRNSHalf-year Report
10th Sep 20197:00 amRNSPreferred Partner Arrangement with Mount Sinai
21st Aug 20197:00 amRNSNotice of Results
8th Aug 20194:40 pmRNSSecond Price Monitoring Extn
8th Aug 20194:35 pmRNSPrice Monitoring Extension
15th Jul 20197:00 amRNSTrading update
11th Jun 20192:15 pmRNSCancellation of share options
7th Jun 20194:30 pmRNSHolding(s) in Company
28th May 20197:00 amRNSDirector/PDMR Shareholding
2nd May 201911:21 amRNSResult of AGM
26th Apr 20196:20 pmRNSAcquisition of further interest in Renalytix AI
25th Apr 20197:00 amRNSPosting of AR & Accounts and Notice of AGM
13th Mar 20197:00 amRNSFinal Results
8th Mar 20197:00 amRNSNotice of Results
20th Feb 20197:00 amRNSUS FDA approval for Quo-Test analyser
22nd Jan 20197:00 amRNSUpdate on McKesson US distribution agreement
21st Jan 20197:00 amRNSClarification re. lock-up restrictions
16th Jan 20197:00 amRNSTrading update
20th Dec 20187:00 amRNSUpdate regarding planned change of NOMAD
19th Dec 20184:56 pmRNSPDMR dealing
7th Dec 20183:15 pmRNSPurchase of own shares and PDMR Dealing
30th Nov 20182:35 pmRNSTotal Voting Rights
22nd Nov 20185:13 pmRNSPurchase of own shares and PDMR Dealing
21st Nov 20182:08 pmRNSPurchase of own shares and PDMR Dealing
20th Nov 20185:18 pmRNSPurchase of own shares and PDMR Dealing
14th Nov 20182:20 pmRNSShare Buy-Back
9th Nov 20181:48 pmRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSRENX Admission to AIM and First Day of Dealings
2nd Nov 20188:00 amRNSSchedule 1 update - Renalytix AI plc
1st Nov 20185:30 pmRNSUpdate regarding AIM admission of RenalytixAI
31st Oct 20186:00 pmRNSResult of RO by RenalytixAI & Fundraising Update
23rd Oct 20182:00 pmRNSSchedule One Update - Renalytix AI plc
23rd Oct 201811:01 amRNSUpdate to distribution timetable
22nd Oct 20185:23 pmRNSApproval of distribution of shares in RenalytixAI
19th Oct 201812:10 pmRNSResult of General Meeting
19th Oct 201811:00 amRNSSchedule One - Renalytix AI plc
12th Oct 20187:00 amRNSInvestor presentation
11th Oct 20186:03 pmRNSLaunch of Restricted Offer by Renalytix AI plc
11th Oct 20185:21 pmRNSFundraising and AIM admission of Renalytix AI plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.